These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12021632)

  • 21. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients.
    Bonhomme-Faivre L; Devocelle A; Saliba F; Chatled S; Maccario J; Farinotti R; Picard V
    Transplantation; 2004 Jul; 78(1):21-5. PubMed ID: 15257034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
    Cho HY; Yoon H; Park GK; Lee YB
    Clin Ther; 2009 Nov; 31(11):2712-21. PubMed ID: 20110013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.
    Foote CJ; Greer W; Kiberd BA; Fraser A; Lawen J; Nashan B; Belitsky P
    Transplant Proc; 2006 Nov; 38(9):2847-9. PubMed ID: 17112845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of cyclosporine after intravenous and multi-dose oral administration in cats.
    Mehl ML; Kyles AE; Craigmill AL; Epstein S; Gregory CR
    J Vet Pharmacol Ther; 2003 Oct; 26(5):349-54. PubMed ID: 14633187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of MDR1 C1236T polymorphism on cyclosporine pharmacokinetics: A systematic review and meta-analysis.
    Chen Z; Zhang L; Yang C; Jiang Z; Shen H; Gui G
    Medicine (Baltimore); 2017 Nov; 96(47):e8700. PubMed ID: 29381954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers.
    Lim MS; Seong SJ; Park J; Seo JJ; Lee J; Yu KS; Lee HW; Yoon YR
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):399-405. PubMed ID: 22404324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
    Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased cyclosporine exposure during the remission of nephrotic syndrome.
    Medeiros M; Pérez-Urizar J; Mejía-Gaviria N; Ramírez-López E; Castañeda-Hernández G; Muñoz R
    Pediatr Nephrol; 2007 Jan; 22(1):84-90. PubMed ID: 17053886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporine bioequivalence study: quantification using fluorescence polarization immunoassay (FPIA) and radioimmunoassay (RIA).
    Mendes GD; de Oliveira CH; Sucupira M; Donato JL; Moreno RA; De Nucci G
    Int J Clin Pharmacol Ther; 2004 Feb; 42(2):125-32. PubMed ID: 15180174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients.
    Kuzuya T; Kobayashi T; Moriyama N; Nagasaka T; Yokoyama I; Uchida K; Nakao A; Nabeshima T
    Transplantation; 2003 Sep; 76(5):865-8. PubMed ID: 14501869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.
    Sakaeda T; Nakamura T; Horinouchi M; Kakumoto M; Ohmoto N; Sakai T; Morita Y; Tamura T; Aoyama N; Hirai M; Kasuga M; Okumura K
    Pharm Res; 2001 Oct; 18(10):1400-4. PubMed ID: 11697464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.